Correction to: Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative
Drug Safety - Trang 1-1 - 2024
Eric B. Cohen1, Meenal Patwardhan1, Ritu Raheja1, David H. Alpers2, Raul J. Andrade3, Mark I. Avigan4, James H. Lewis5, Don C. Rockey6, Francis Chui7, Alexandru M. Iacob8, Camila C. Linardi9, Arie Regev10, Jesse Shick7, M. Isabel Lucena11
1Pharmacovigilance and Patient Safety, AbbVie Inc., North Chicago, USA
2Department of Medicine, Washington University School of Medicine, St Louis, USA.
3Department of Medicine, IBIMA_Plataforma Bionand, University of Malaga, Malaga, Spain
4Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, USA
5Division of Gastroenterology, Georgetown University, Washington, USA
6Digestive Disease Research Center, Medical University of South Carolina, Charleston, USA
7Pharmacovigilance, Gilead Sciences Inc., Foster City, USA
8Pharmacovigilance and Patient Safety, AbbVie Inc., Ottawa, Canada
9Translational Medicine, Bayer HealthCare Pharmaceuticals LLC, Whippany, USA
10Global Patient Safety, Eli Lilly and Company, Indianapolis, USA
11Department of Pharmacology and Pediatrics, IBIMA_Plataforma Bionand, University of Malaga, Malaga, Spain